Titre : Protéines de liaison au TGF-bêta latent

Protéines de liaison au TGF-bêta latent : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cisplatin
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Protéines de liaison au TGF-bêta latent : Questions médicales les plus fréquentes", "headline": "Protéines de liaison au TGF-bêta latent : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Protéines de liaison au TGF-bêta latent : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-18", "dateModified": "2025-04-14", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Protéines de liaison au TGF-bêta latent" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines de la matrice extracellulaire", "url": "https://questionsmedicales.fr/mesh/D016326", "about": { "@type": "MedicalCondition", "name": "Protéines de la matrice extracellulaire", "code": { "@type": "MedicalCode", "code": "D016326", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.860.300" } } }, "about": { "@type": "MedicalCondition", "name": "Protéines de liaison au TGF-bêta latent", "alternateName": "Latent TGF-beta Binding Proteins", "code": { "@type": "MedicalCode", "code": "D053779", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Nalani Sachan", "url": "https://questionsmedicales.fr/author/Nalani%20Sachan", "affiliation": { "@type": "Organization", "name": "Department of Cell Biology, NYU Grossman School of Medicine, New York, New York, USA." } }, { "@type": "Person", "name": "Hui Liu", "url": "https://questionsmedicales.fr/author/Hui%20Liu", "affiliation": { "@type": "Organization", "name": "Department of Experimental Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, 710038, Shanxi, China." } }, { "@type": "Person", "name": "Daniel Rifkin", "url": "https://questionsmedicales.fr/author/Daniel%20Rifkin", "affiliation": { "@type": "Organization", "name": "Department of Cell Biology, NYU Grossman School of Medicine, New York, New York, USA." } }, { "@type": "Person", "name": "Karan Singh", "url": "https://questionsmedicales.fr/author/Karan%20Singh", "affiliation": { "@type": "Organization", "name": "Department of Cell Biology, NYU Grossman School of Medicine, New York, New York, USA." } }, { "@type": "Person", "name": "Hong-Lian Wang", "url": "https://questionsmedicales.fr/author/Hong-Lian%20Wang", "affiliation": { "@type": "Organization", "name": "Research Center for Integrative Medicine, The Affiliated Traditional Medicine Hospital of Southwest Medical University, Luzhou 646000, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Cisplatin Binding to Human Serum Transferrin: A Crystallographic Study.", "datePublished": "2023-01-05", "url": "https://questionsmedicales.fr/article/36602395", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/acs.inorgchem.2c04206" } }, { "@type": "ScholarlyArticle", "name": "Cisplatin Nephrotoxicity: Novel Insights Into Mechanisms and Preventative Strategies.", "datePublished": "2023-05-12", "url": "https://questionsmedicales.fr/article/37182407", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.semnephrol.2023.151341" } }, { "@type": "ScholarlyArticle", "name": "PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin.", "datePublished": "2023-02-23", "url": "https://questionsmedicales.fr/article/36823640", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13018-023-03615-w" } }, { "@type": "ScholarlyArticle", "name": "MicroRNAs as Predictors of Lung-Cancer Resistance and Sensitivity to Cisplatin.", "datePublished": "2022-07-08", "url": "https://questionsmedicales.fr/article/35886942", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms23147594" } }, { "@type": "ScholarlyArticle", "name": "Hypoxia, but Not Normoxia, Reduces Effects of Resveratrol on Cisplatin Treatment in A2780 Ovarian Cancer Cells: A Challenge for Resveratrol Use in Anticancer Adjuvant Cisplatin Therapy.", "datePublished": "2023-03-16", "url": "https://questionsmedicales.fr/article/36982788", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms24065715" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Scléroprotéines", "item": "https://questionsmedicales.fr/mesh/D012596" }, { "@type": "ListItem", "position": 5, "name": "Protéines de la matrice extracellulaire", "item": "https://questionsmedicales.fr/mesh/D016326" }, { "@type": "ListItem", "position": 6, "name": "Protéines de liaison au TGF-bêta latent", "item": "https://questionsmedicales.fr/mesh/D053779" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Protéines de liaison au TGF-bêta latent - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Protéines de liaison au TGF-bêta latent", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-03", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Protéines de liaison au TGF-bêta latent", "description": "Comment diagnostiquer une anomalie des protéines de liaison au TGF-bêta ?\nQuels tests sont utilisés pour évaluer le TGF-bêta ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels symptômes peuvent indiquer un problème avec le TGF-bêta ?\nY a-t-il des marqueurs spécifiques pour ces protéines ?", "url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cisplatin&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Protéines de liaison au TGF-bêta latent", "description": "Quels symptômes sont associés à une dysfonction du TGF-bêta ?\nLa douleur est-elle un symptôme courant ?\nPeut-on observer des anomalies cutanées ?\nLes troubles respiratoires sont-ils liés au TGF-bêta ?\nY a-t-il des signes d'inflammation systémique ?", "url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cisplatin&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Protéines de liaison au TGF-bêta latent", "description": "Comment prévenir les troubles liés au TGF-bêta ?\nY a-t-il des mesures spécifiques à prendre ?\nLes vaccinations sont-elles importantes ?\nL'éducation des patients est-elle cruciale ?\nLe suivi médical régulier est-il recommandé ?", "url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cisplatin&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Protéines de liaison au TGF-bêta latent", "description": "Quels traitements sont disponibles pour les troubles liés au TGF-bêta ?\nLa thérapie génique est-elle une option ?\nLes corticostéroïdes sont-ils utilisés ?\nY a-t-il des traitements expérimentaux ?\nLes changements de mode de vie peuvent-ils aider ?", "url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cisplatin&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Protéines de liaison au TGF-bêta latent", "description": "Quelles complications peuvent survenir ?\nLes complications cardiovasculaires sont-elles possibles ?\nY a-t-il un risque accru de cancer ?\nLes troubles neurologiques peuvent-ils être liés ?\nComment gérer les complications ?", "url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cisplatin&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Protéines de liaison au TGF-bêta latent", "description": "Quels sont les principaux facteurs de risque ?\nLe vieillissement est-il un facteur de risque ?\nL'obésité influence-t-elle le risque ?\nLe stress a-t-il un impact ?\nLes infections peuvent-elles être un facteur ?", "url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cisplatin&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie des protéines de liaison au TGF-bêta ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sanguins et des analyses génétiques pour détecter des mutations." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer le TGF-bêta ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des dosages immunologiques et des tests ELISA sont couramment utilisés pour mesurer le TGF-bêta." } }, { "@type": "Question", "name": "Les biopsies sont-elles nécessaires pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des biopsies peuvent être effectuées pour évaluer les tissus affectés et la présence de TGF-bêta." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec le TGF-bêta ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme l'inflammation chronique ou des troubles de cicatrisation peuvent indiquer un problème." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour ces protéines ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des marqueurs comme le TGF-bêta actif peuvent être utilisés pour évaluer leur fonction." } }, { "@type": "Question", "name": "Quels symptômes sont associés à une dysfonction du TGF-bêta ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des troubles immunitaires, des fibroses et des anomalies de cicatrisation." } }, { "@type": "Question", "name": "La douleur est-elle un symptôme courant ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs peuvent survenir en raison d'inflammation ou de fibrose tissulaire." } }, { "@type": "Question", "name": "Peut-on observer des anomalies cutanées ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies cutanées comme des cicatrices hypertrophiques peuvent se produire." } }, { "@type": "Question", "name": "Les troubles respiratoires sont-ils liés au TGF-bêta ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles respiratoires peuvent survenir en raison de fibrose pulmonaire associée." } }, { "@type": "Question", "name": "Y a-t-il des signes d'inflammation systémique ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des signes comme la fièvre et la fatigue peuvent indiquer une inflammation systémique." } }, { "@type": "Question", "name": "Comment prévenir les troubles liés au TGF-bêta ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par un mode de vie sain et la gestion des maladies inflammatoires." } }, { "@type": "Question", "name": "Y a-t-il des mesures spécifiques à prendre ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Éviter le tabac et l'alcool peut réduire le risque de complications liées au TGF-bêta." } }, { "@type": "Question", "name": "Les vaccinations sont-elles importantes ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vaccinations peuvent aider à prévenir les infections qui exacerbent les troubles." } }, { "@type": "Question", "name": "L'éducation des patients est-elle cruciale ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, informer les patients sur les symptômes et les facteurs de risque est essentiel." } }, { "@type": "Question", "name": "Le suivi médical régulier est-il recommandé ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi médical régulier permet de détecter précocement les anomalies." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les troubles liés au TGF-bêta ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des médicaments anti-inflammatoires et des thérapies ciblées." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la thérapie génique est explorée pour corriger des anomalies génétiques liées au TGF-bêta." } }, { "@type": "Question", "name": "Les corticostéroïdes sont-ils utilisés ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les corticostéroïdes peuvent être prescrits pour réduire l'inflammation associée." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements expérimentaux, comme les inhibiteurs de TGF-bêta, sont en cours d'évaluation." } }, { "@type": "Question", "name": "Les changements de mode de vie peuvent-ils aider ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des changements comme une alimentation saine et l'exercice peuvent améliorer les symptômes." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des fibroses, des troubles respiratoires et des maladies auto-immunes." } }, { "@type": "Question", "name": "Les complications cardiovasculaires sont-elles possibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications cardiovasculaires peuvent survenir en raison d'une inflammation chronique." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des études suggèrent un lien entre TGF-bêta et certains types de cancer." } }, { "@type": "Question", "name": "Les troubles neurologiques peuvent-ils être liés ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles neurologiques peuvent être associés à des déséquilibres du TGF-bêta." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite une approche multidisciplinaire et un suivi régulier." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, des maladies auto-immunes et l'exposition à des toxines." } }, { "@type": "Question", "name": "Le vieillissement est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement peut augmenter le risque de dysfonction des protéines de liaison au TGF-bêta." } }, { "@type": "Question", "name": "L'obésité influence-t-elle le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'obésité est associée à une inflammation chronique, augmentant le risque de troubles." } }, { "@type": "Question", "name": "Le stress a-t-il un impact ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut exacerber les troubles liés au TGF-bêta." } }, { "@type": "Question", "name": "Les infections peuvent-elles être un facteur ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines infections peuvent déclencher des réponses inflammatoires affectant le TGF-bêta." } } ] } ] }

Sources (2912 au total)

PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin.

Osteosarcoma is a common primary bone malignancy prevalent among adolescents and young adults. PTEN-induced kinase 1 (PINK1) regulates Parkinson's disease, but its role in cancers is unknown.... This study was designed to analyze the mechanism by which PINK1 affects osteosarcoma using bioinformatics and cell experiments.... The gene expression profiles were downloaded from the TARGET database. Several online databases were used to analyze the expression and protein‒protein interaction networks. CCK-8 cell viability assay... Through bioinformatics analysis, we found that high expression of PINK1 was associated with poor prognosis in patients with osteosarcoma, and PINK1 inhibited apoptosis and promoted proliferation pathw... Collectively, our findings demonstrate that PINK1 is crucially involved in osteosarcoma and suggests that it can promote the apoptosis of OS cells as the downstream target gene of cisplatin....

MicroRNAs as Predictors of Lung-Cancer Resistance and Sensitivity to Cisplatin.

Platinum-based chemotherapy, cisplatin (DDP) specifically, is the main strategy for treating lung cancer (LC). However, currently, there is a lack of predictive drug-resistance markers, and there is i... Data on miRNAs associated with LC DDP chemotherapy response are summarized and analyzed.... A comprehensive review of the data in the literature and an analysis of bioinformatics resources were performed. The gene targets of miRNAs, as well as their reciprocal relationships with miRNAs, were... The complex analysis of bioinformatics resources and the literature indicated that the expressions of 12 miRNAs have a high predictive potential for LC DDP chemotherapy responses. The obtained informa... An overview of the published data and bioinformatics resources, with respect to the predictive microRNA markers of chemotherapy response, is presented in this review. The selected microRNAs and gene p...

Hypoxia, but Not Normoxia, Reduces Effects of Resveratrol on Cisplatin Treatment in A2780 Ovarian Cancer Cells: A Challenge for Resveratrol Use in Anticancer Adjuvant Cisplatin Therapy.

Natural compounds, such as resveratrol (Res), are currently used as adjuvants for anticancer therapies. To evaluate the effectiveness of Res for the treatment of ovarian cancer (OC), we screened the r...

Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).

Gemcitabine/cisplatin (GC) combination therapy has been the standard palliative chemotherapy for patients with advanced biliary tract cancer (BTC). No randomized clinical trials have been able to demo... We performed a mulitcenter, randomized phase III trial across 39 centers. Enrolled patients were randomly allocated (1:1) to either the GCS or GC arm. The GCS regimen comprised gemcitabine (1000 mg/m... Between July 2014 and February 2016, 246 patients were enrolled. The median OS and 1-year OS rate were 13.5 months and 59.4% in the GCS arm and 12.6 months and 53.7% in the GC arm, respectively (hazar... GCS is the first regimen which demonstrated survival benefits as well as higher RR over GC in a randomized phase III trial and could be the new first-line standard chemotherapy for advanced BTC. To ex...

MiR-375 promotes cisplatin sensitivity of lung adenocarcinoma.

Cisplatin-based chemotherapy has been widely used in the treatment of lung adenocarcinoma (LUAD). However, the development of cisplatin resistance becomes a major obstacle impeding the curative effect... Based on the CCLE database, lung cancer cell lines were divided into cisplatin-resistant and cisplatin-sensitive groups. The differentially expressed miRNAs were filtered and further identified by sur... In this study, miR-375 showed the ability to promote cisplatin sensitivity and apoptosis of LUAD. Genes correlated with miR-375 in LUAD were analyzed and ABCC8 showed the strongest positive correlatio... Overall, this study provides new insights into the role of miR-375 in the cisplatin sensitivity of LUAD. Our present findings may serve as a theoretical basis for new therapeutic strategies and predic...